SG Trading Solutions LLC Acquires Shares of 43,758 Takeda Pharmaceutical Co. $TAK

SG Trading Solutions LLC bought a new stake in Takeda Pharmaceutical Co. (NYSE:TAK) during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor bought 43,758 shares of the company’s stock, valued at approximately $682,000.

Several other institutional investors and hedge funds also recently made changes to their positions in the business. Private Trust Co. NA raised its stake in shares of Takeda Pharmaceutical by 84.7% in the 4th quarter. Private Trust Co. NA now owns 1,707 shares of the company’s stock valued at $27,000 after purchasing an additional 783 shares in the last quarter. Parkside Financial Bank & Trust lifted its position in shares of Takeda Pharmaceutical by 192.2% during the fourth quarter. Parkside Financial Bank & Trust now owns 2,560 shares of the company’s stock worth $40,000 after purchasing an additional 1,684 shares during the last quarter. Caitong International Asset Management Co. Ltd grew its stake in Takeda Pharmaceutical by 313.7% in the fourth quarter. Caitong International Asset Management Co. Ltd now owns 3,070 shares of the company’s stock worth $48,000 after purchasing an additional 2,328 shares in the last quarter. Northwestern Mutual Wealth Management Co. grew its stake in Takeda Pharmaceutical by 56.3% in the second quarter. Northwestern Mutual Wealth Management Co. now owns 3,586 shares of the company’s stock worth $55,000 after purchasing an additional 1,292 shares in the last quarter. Finally, Harbour Investments Inc. increased its holdings in Takeda Pharmaceutical by 300.3% in the fourth quarter. Harbour Investments Inc. now owns 4,612 shares of the company’s stock valued at $72,000 after buying an additional 3,460 shares during the last quarter. 9.17% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

TAK has been the topic of several research reports. Weiss Ratings restated a “hold (c)” rating on shares of Takeda Pharmaceutical in a research note on Wednesday, April 29th. Zacks Research upgraded Takeda Pharmaceutical from a “strong sell” rating to a “hold” rating in a research report on Tuesday, March 3rd. Wall Street Zen downgraded Takeda Pharmaceutical from a “strong-buy” rating to a “buy” rating in a report on Saturday, May 16th. Finally, Sanford C. Bernstein raised Takeda Pharmaceutical from a “market perform” rating to an “outperform” rating in a research report on Wednesday, April 8th. Two research analysts have rated the stock with a Buy rating and two have given a Hold rating to the company. According to MarketBeat, Takeda Pharmaceutical has a consensus rating of “Moderate Buy”.

Takeda Pharmaceutical Trading Up 1.4%

NYSE TAK opened at $15.63 on Friday. The company has a debt-to-equity ratio of 0.56, a quick ratio of 0.70 and a current ratio of 1.27. Takeda Pharmaceutical Co. has a one year low of $12.99 and a one year high of $18.90. The company has a 50-day simple moving average of $16.49 and a 200-day simple moving average of $16.75. The firm has a market capitalization of $49.76 billion, a PE ratio of 40.09 and a beta of -0.07.

Takeda Pharmaceutical (NYSE:TAK) last released its quarterly earnings data on Tuesday, March 31st. The company reported $0.56 earnings per share for the quarter. Takeda Pharmaceutical had a net margin of 4.31% and a return on equity of 11.07%. The firm had revenue of $6.90 billion for the quarter. On average, equities analysts forecast that Takeda Pharmaceutical Co. will post 0.94 earnings per share for the current year.

Takeda Pharmaceutical Company Profile

Takeda Pharmaceutical Company Limited (NYSE: TAK) is a Tokyo-based, multinational biopharmaceutical company with roots dating back to 1781. The company researches, develops, manufactures and commercializes pharmaceutical and biopharmaceutical products for patients worldwide. Takeda is publicly listed and operates as a fully integrated R&D-driven healthcare company focused on delivering specialty medicines and therapies across a range of therapeutic areas.

Takeda’s main business activities encompass discovery and development of prescription medicines, clinical development and regulatory affairs, manufacturing of small molecules and biologics, and global commercial operations.